The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder

11 September 2019.

Kasper Recourt, Peter de Boer, Rob Zuiker, Remy Luthringer, Justine Kent, Peter van der Ark, Ilse Van Hove, Joop van Gerven, Gabriel Jacobs, Luc van Nueten and Wayne Drevets